about
The danger theory: 20 years laterExploiting tumor epigenetics to improve oncolytic virotherapyInterferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancerInterferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancerKnockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cellsRegulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interactionIRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cellsThe interferon stimulated gene 54 promotes apoptosisBBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage responseNeutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor modelA human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responsesInterferon-γ links ultraviolet radiation to melanomagenesis in miceTumor-specific Th17-polarized cells eradicate large established melanomaNecroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapyTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?HZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary CarcinogenesisCytokine-Induced Modulation of Colorectal CancerThe role of BST-2/Tetherin in host protection and disease manifestationStaphylococcal Superantigens Spark Host-Mediated Danger SignalsHistorical review of the causes of cancerMPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsPI3K/Akt/mTOR, a pathway less recognized for staphylococcal superantigen-induced toxicityFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsShedding light on melanocyte pathobiology in vivoImmune cell promotion of metastasisTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsAdvances in the understanding of cancer immunotherapyPost-transcriptional regulation of interferons and their signaling pathwaysSTAT3 inhibitors for cancer therapy: Have all roads been explored?Combining radiotherapy and cancer immunotherapy: a paradigm shiftType I interferon response and innate immune sensing of cancerInflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusionsNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewStromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in miceIncreased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient miceA globally occurring indel polymorphism in the promoter of the IFNA2 gene is not associated with severity of malaria but with the positivity rate of HCVCancer immunoediting: integrating immunity's roles in cancer suppression and promotionImmunity, Inflammation, and Cancer
P2860
Q21131221-BABD4D3B-3D7B-415D-9F11-4A02EE6BEA13Q21131237-B10D2EA7-5162-46A8-83F8-9148F4A2B137Q24202094-E1BE34D3-5B8D-4C25-8D8A-CE0606D7DF73Q24203808-6A36EFF1-E171-4899-94F7-093873DA4DF2Q24299700-E7F34948-E43B-48D2-92BA-FA012AD7D4B5Q24309134-7560B2F0-FFEB-4B19-BAF1-AD2DD9BAB5A1Q24310103-8CB4253D-6D6B-43B0-976E-FCFF4C5A7EE4Q24321910-0E2143B8-F22A-40A3-9B79-9B788977218CQ24323889-BCE552E6-84AB-46FF-87A7-F1AD67935B91Q24612339-C80D8A30-288C-4347-9C7C-5BE7A636BDADQ24630221-18D34889-A171-4C6E-AB07-9C8DD3F9F47BQ24631120-7A2D5736-9F84-4D60-A99A-3C1F883B7773Q24648032-2E566D55-0599-44BD-930D-CAF3B1ED3DBBQ26739959-B02546EE-DF3F-40C6-9ED1-18304A9B8B23Q26745446-7A59E913-82FE-4B05-8C83-8CD0CC5E25B0Q26747695-99937756-8AE4-4D02-96EE-0A90D86A7E7AQ26750868-504BFFC8-C83A-493E-B9ED-73D302F291A9Q26752374-7DB58EA4-4B01-4D8A-B779-DB3EFCE6E618Q26752737-67CC5A87-FB9C-43AD-995D-264F9BB00F87Q26766421-657E2470-F72E-45EA-8DE5-A3CAAED8F263Q26767036-EA4577DD-DB17-4F11-9C8E-E447DB86BA2AQ26775996-D4601DCE-B6EF-4F2D-A28B-EB5E1012B244Q26781538-4D6B1CD0-11FE-4629-94BF-1E6BACA1F6B6Q26825729-0EB4FDAD-011A-4D3E-B2EE-3070B45E2CBFQ26865532-D9A8ACA7-4CEA-46D2-9CBF-2BBDC73992CCQ26866190-698C165E-E86D-4F4F-8676-1C6D945968C0Q26991724-F5DD67F9-1CEA-43E9-A0C7-C8551145412AQ26996518-D9A0D10A-B2F4-4894-BF73-8A346B6B04DFQ27000706-6070AB1E-F8F3-4960-9AB8-E2D475C04BB7Q27014043-476FDCDD-B8BF-47B4-98C2-BF272EA5E7D4Q27021266-03AD4DDE-C1A6-4F7A-9E99-5B8071D1A363Q27021428-FAEE5238-14BA-4442-A4F3-7C1440A07A26Q27023235-CEFBB2F5-9777-461E-9B6B-5BF06C9AA297Q27023584-BF045EE6-03C2-42CF-86AB-83DF80CB99ADQ27304386-36F50B4B-4D60-4379-842F-3F564EBCA5B0Q27305136-CC535572-9715-416C-BF0C-9C60438A14E3Q27330218-9BBD428A-7DDD-4217-8029-464EE336CD13Q27487536-60B19A2A-5692-418C-B903-094E98CED8FBQ27860475-024AAA93-5D84-4065-91B0-AB2BAA3EDADFQ27861048-39111EDE-9D91-44C1-BF99-A252644773F4
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Interferons, immunity and cancer immunoediting
@ast
Interferons, immunity and cancer immunoediting
@en
Interferons, immunity and cancer immunoediting
@nl
type
label
Interferons, immunity and cancer immunoediting
@ast
Interferons, immunity and cancer immunoediting
@en
Interferons, immunity and cancer immunoediting
@nl
prefLabel
Interferons, immunity and cancer immunoediting
@ast
Interferons, immunity and cancer immunoediting
@en
Interferons, immunity and cancer immunoediting
@nl
P2093
P3181
P356
P1476
Interferons, immunity and cancer immunoediting
@en
P2093
Catherine M Koebel
Gavin P Dunn
Robert D Schreiber
P2888
P304
P3181
P356
10.1038/NRI1961
P407
P577
2006-11-01T00:00:00Z
P5875
P6179
1034368267